IVC Wealth Advisors LLC Sells 207 Shares of IQVIA Holdings Inc. (NYSE:IQV)

IVC Wealth Advisors LLC reduced its position in IQVIA Holdings Inc. (NYSE:IQV) by 8.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,269 shares of the medical research company’s stock after selling 207 shares during the period. IVC Wealth Advisors LLC’s holdings in IQVIA were worth $446,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the company. Capital Performance Advisors LLP bought a new position in shares of IQVIA during the 3rd quarter valued at approximately $27,000. Park Place Capital Corp purchased a new position in shares of IQVIA in the 3rd quarter worth $28,000. Avior Wealth Management LLC increased its holdings in shares of IQVIA by 117.6% in the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after buying an additional 87 shares during the last quarter. Assetmark Inc. lifted its holdings in shares of IQVIA by 612.5% in the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after acquiring an additional 196 shares during the last quarter. Finally, UMB Bank n.a. grew its position in IQVIA by 74.4% in the third quarter. UMB Bank n.a. now owns 232 shares of the medical research company’s stock worth $55,000 after acquiring an additional 99 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

IQV has been the subject of several analyst reports. Leerink Partners reaffirmed an “outperform” rating and issued a $248.00 price objective (down from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. TD Cowen dropped their price objective on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, November 1st. The Goldman Sachs Group reduced their target price on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Barclays cut their price target on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Finally, StockNews.com downgraded IQVIA from a “buy” rating to a “hold” rating in a report on Thursday, November 28th. Four research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $255.71.

IQVIA Stock Performance

Shares of IQVIA stock opened at $206.06 on Friday. IQVIA Holdings Inc. has a one year low of $187.62 and a one year high of $261.73. The company has a market capitalization of $37.40 billion, a PE ratio of 27.04, a P/E/G ratio of 2.14 and a beta of 1.48. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The company has a 50-day simple moving average of $199.41 and a two-hundred day simple moving average of $221.19.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.